Mesoblast (NASDAQ:MESO – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Tuesday.
Several other equities research analysts have also commented on MESO. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a research report on Thursday, June 20th. Piper Sandler raised shares of Mesoblast from a “neutral” rating to an “overweight” rating and upped their target price for the company from $4.00 to $11.00 in a report on Tuesday, July 23rd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.50.
Read Our Latest Stock Analysis on Mesoblast
Mesoblast Stock Performance
Institutional Trading of Mesoblast
A number of hedge funds and other institutional investors have recently bought and sold shares of MESO. GAMMA Investing LLC boosted its holdings in Mesoblast by 50.1% in the 2nd quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after buying an additional 1,663 shares during the period. Perkins Coie Trust Co purchased a new position in shares of Mesoblast during the second quarter valued at about $68,000. Pine Valley Investments Ltd Liability Co bought a new stake in shares of Mesoblast in the second quarter worth about $80,000. Chapin Davis Inc. lifted its position in shares of Mesoblast by 50.0% in the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock worth $102,000 after buying an additional 5,000 shares in the last quarter. Finally, Chase Investment Counsel Corp bought a new position in Mesoblast during the first quarter valued at approximately $298,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.
Mesoblast Company Profile
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
- Five stocks we like better than Mesoblast
- What is an Earnings Surprise?
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- Are Penny Stocks a Good Fit for Your Portfolio?
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- Bank Stocks – Best Bank Stocks to Invest In
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.